Cytomegalovirus immune globulin - MedImmune

Drug Profile

Cytomegalovirus immune globulin - MedImmune

Alternative Names: CMV-IGIV; CytoGam

Latest Information Update: 22 Apr 2013

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator MedImmune
  • Class Antivirals; Immunoglobulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Marketed Cytomegalovirus infections

Most Recent Events

  • 30 Apr 2012 CSL initiates enrolment in a phase III trial for Cytomegalovirus infections (prevention of congenital CMV) in the US (NCT01376778)
  • 19 Jun 2007 MedImmune has been acquired by AstraZeneca
  • 08 Jan 2007 ZLB Behring is now called CSL Pharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top